acetaminophen has been researched along with Coxarthrosis in 65 studies
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.
paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study compared the efficacy and safety of low-dose 7-day buprenorphine patches and prolonged-release tramadol tablets in patients with chronic, moderate to severe osteoarthritis (OA) pain of the hip and/or knee." | 9.14 | Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, pa ( Berggren, AC; Karlsson, M, 2009) |
| "To examine, in routine practice, the effectiveness and cost-effectiveness of oxycodone (OxyContin) compared with standard therapy for osteoarthritis pain." | 9.12 | Economic evaluation of controlled-release oxycodone vs oxycodone-acetaminophen for osteoarthritis pain of the hip or knee. ( Buitendyk, M; Codding, C; Marshall, DA; Pericak, D; Strauss, ME; Torrance, GW, 2006) |
| "Long-term treatment with tramadol LP once daily is generally safe in patients with osteoarthritis or refractory low back pain." | 9.11 | Long-term tolerability of tramadol LP, a new once-daily formulation, in patients with osteoarthritis or low back pain. ( Coffiner, M; Fontaine, D; Malonne, H; Peretz, A; Sereno, A; Sonet, B; Vanderbist, F, 2005) |
| "In a double-blind study of 18 patients with coxarthrosis the effect of 3 naproxen doses (0." | 9.07 | Naproxen and paracetamol compared with naproxen only in coxarthrosis. Increased effect of the combination in 18 patients. ( Neander, G; Samuelson, P; Seideman, P, 1993) |
| "A double-blind randomized parallel group trial was undertaken to compare the acceptability and efficacy of 2 forms of analgesic treatment, DI-Antalvic (Houde Laboratories, Puteaux, France) (30 mg dextropropoxyphene and 400 mg paracetamol per capsule) and Efferalgan-Codeine (UPSA Laboratories, Rueil Malmaison, France) (30 mg codeine and 500 mg paracetamol per tablet) prescribed for 1 week at doses of 6 capsules/day and 6 tablets/day, respectively, in 141 outpatients with active osteoarthritis of the knee or hip." | 9.07 | Acceptability and efficacy of two associations of paracetamol with a central analgesic (dextropropoxyphene or codeine): comparison in osteoarthritis. ( Boissier, C; Decousus, H; Gayet, JL; Hocquart, J; Laporte-Simitsidis, S; Mismetti, P; Perpoint, B; Queneau, P; Rambaud, C, 1992) |
| "In patients with chronic pain, oral analgesics are essential treatment options to manage pain appropriately, improve activities of daily living abilities and achieve a higher quality of life (QOL)." | 7.30 | Protocol for the RETHINK study: a randomised, double-blind, parallel-group, non-inferiority clinical trial comparing acetaminophen and NSAIDs for treatment of chronic pain in elderly patients with osteoarthritis of the hip and knee. ( Aono, H; Endo, M; Hara, T; Kawahara, S; Kawano, T; Mawatari, T; Miyaji, T; Miyake, M; Nakashima, Y; Sakamoto, S; Sato, T; Shimokawa, M; Takano, T; Tokunaga, M; Zenda, S, 2023) |
| " IR/ER HB/APAP tablets deliver 25% of the HB dose and 50% of the APAP dose by IR and the remainder by ER over a 12-hour dosing interval." | 6.80 | Tolerability of Biphasic-Release Hydrocodone Bitartrate/Acetaminophen Tablets (MNK-155): A Phase III, Multicenter, Open-Label Study in Patients With Osteoarthritis or Chronic Low Back Pain. ( Barrett, T; Chen, Y; Giuliani, MJ; Hisaw, E; Kostenbader, K; Young, JL; Zheng, Y, 2015) |
| "This randomized, double-blind study enrolled patients ≥40 years of age with confirmed hip or knee OA (Kellgren-Lawrence grade II-III) who were chronic users of NSAIDs and/or acetaminophen for OA pain and had Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale mean scores ≥40 mm." | 5.20 | Efficacy and safety of low-dose SoluMatrix meloxicam in the treatment of osteoarthritis pain: a 12-week, phase 3 study. ( Altman, R; Gibofsky, A; Hochberg, M; Jaros, M; Young, C, 2015) |
| "This study compared the efficacy and safety of low-dose 7-day buprenorphine patches and prolonged-release tramadol tablets in patients with chronic, moderate to severe osteoarthritis (OA) pain of the hip and/or knee." | 5.14 | Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, pa ( Berggren, AC; Karlsson, M, 2009) |
| "To examine, in routine practice, the effectiveness and cost-effectiveness of oxycodone (OxyContin) compared with standard therapy for osteoarthritis pain." | 5.12 | Economic evaluation of controlled-release oxycodone vs oxycodone-acetaminophen for osteoarthritis pain of the hip or knee. ( Buitendyk, M; Codding, C; Marshall, DA; Pericak, D; Strauss, ME; Torrance, GW, 2006) |
| "Long-term treatment with tramadol LP once daily is generally safe in patients with osteoarthritis or refractory low back pain." | 5.11 | Long-term tolerability of tramadol LP, a new once-daily formulation, in patients with osteoarthritis or low back pain. ( Coffiner, M; Fontaine, D; Malonne, H; Peretz, A; Sereno, A; Sonet, B; Vanderbist, F, 2005) |
| "In a double-blind study of 18 patients with coxarthrosis the effect of 3 naproxen doses (0." | 5.07 | Naproxen and paracetamol compared with naproxen only in coxarthrosis. Increased effect of the combination in 18 patients. ( Neander, G; Samuelson, P; Seideman, P, 1993) |
| "A double-blind randomized parallel group trial was undertaken to compare the acceptability and efficacy of 2 forms of analgesic treatment, DI-Antalvic (Houde Laboratories, Puteaux, France) (30 mg dextropropoxyphene and 400 mg paracetamol per capsule) and Efferalgan-Codeine (UPSA Laboratories, Rueil Malmaison, France) (30 mg codeine and 500 mg paracetamol per tablet) prescribed for 1 week at doses of 6 capsules/day and 6 tablets/day, respectively, in 141 outpatients with active osteoarthritis of the knee or hip." | 5.07 | Acceptability and efficacy of two associations of paracetamol with a central analgesic (dextropropoxyphene or codeine): comparison in osteoarthritis. ( Boissier, C; Decousus, H; Gayet, JL; Hocquart, J; Laporte-Simitsidis, S; Mismetti, P; Perpoint, B; Queneau, P; Rambaud, C, 1992) |
| "A double-blind multicenter cross-over study was conducted on 166 outpatients with painful chronic osteoarthritis of the hip and of the femoro-tibial joints, to compare the effectiveness of glafenine and paracetamol." | 5.06 | A method for comparing analgesics: glafenine and paracetamol. Multicenter cross-over approach. ( Amor, B; Benarrosh, C, 1988) |
| "In patients with chronic pain, oral analgesics are essential treatment options to manage pain appropriately, improve activities of daily living abilities and achieve a higher quality of life (QOL)." | 3.30 | Protocol for the RETHINK study: a randomised, double-blind, parallel-group, non-inferiority clinical trial comparing acetaminophen and NSAIDs for treatment of chronic pain in elderly patients with osteoarthritis of the hip and knee. ( Aono, H; Endo, M; Hara, T; Kawahara, S; Kawano, T; Mawatari, T; Miyaji, T; Miyake, M; Nakashima, Y; Sakamoto, S; Sato, T; Shimokawa, M; Takano, T; Tokunaga, M; Zenda, S, 2023) |
| " IR/ER HB/APAP tablets deliver 25% of the HB dose and 50% of the APAP dose by IR and the remainder by ER over a 12-hour dosing interval." | 2.80 | Tolerability of Biphasic-Release Hydrocodone Bitartrate/Acetaminophen Tablets (MNK-155): A Phase III, Multicenter, Open-Label Study in Patients With Osteoarthritis or Chronic Low Back Pain. ( Barrett, T; Chen, Y; Giuliani, MJ; Hisaw, E; Kostenbader, K; Young, JL; Zheng, Y, 2015) |
| "Hip and knee osteoarthritis is highly prevalent in the elderly, and the incidence is estimated to increase in the coming decades." | 2.77 | Treatment satisfaction after switching to another therapy in Spanish orthopaedic clinic outpatients with knee or hip osteoarthritis previously refractory to paracetamol. ( Armada, B; Marín, MT; Oteo-Álvaro, A; Rejas, J; Ruiz-Ibán, MA, 2012) |
| "3% of the oral NSAIDs, topical NSAIDs, and opioids, respectively, had an increased risk of dropouts due to adverse events." | 2.72 | Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis. ( Almeida, MO; Bobos, P; Bodmer, NS; Cheng, PS; da Costa, BR; Gao, L; Hari, R; Hawker, GA; Hincapié, CA; Iskander, SM; Jüni, P; Kiyomoto, HD; Montezuma, T; Pereira, TV; Rudnicki, M; Saadat, P; Sutton, AJ; Tugwell, P, 2021) |
| " No statistically significant differences were observed between the 2 treatment groups in the proportion of patients who reported > or = 1 adverse event (206 [71." | 2.72 | Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6-12 months) safety of acetaminophen in adult patients with osteoarthritis. ( Benson, GD; Schweinle, JE; Temple, AR; Zinsenheim, JR, 2006) |
| "Acetaminophen was more efficacious than placebo, generally p<0." | 2.71 | Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. ( Fort, JG; Gibofsky, A; Koch, G; Lei, H; Mangal, B; Moskowitz, R; Pincus, T; Simon, L; Sokka, T; Wolfe, F; Zlotnick, S, 2004) |
| "Patients with osteoarthritis of the hip or knee had significantly greater improvements in pain scores over 6 weeks with diclofenac + misoprostol than with acetaminophen, although patients with mild osteoarthritis had similar improvements with both drugs." | 2.70 | A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. ( Abramson, SB; Caldwell, JR; Callahan, LF; Cummins, P; Fort, J; Harrell, RA; Jordan, JM; Koch, GG; Kremer, JM; Lautzenheiser, RL; Lefkowith, J; Luta, G; Markenson, JA; Morant, S; Pincus, T; Schnitzer, TJ; Schwartz, T; Sokka, T; Wang, X; Weaver, A; Wilson, A; Wolfe, F, 2001) |
| "After 2-weeks' treatment, pain on passive movement of the hip joint was statistically significantly less severe on CR dihydrocodeine than on dextropropoxyphene/paracetamol (p = 0." | 2.67 | The efficacy and tolerability of controlled-release dihydrocodeine tablets and combination dextropropoxyphene/paracetamol tablets in patients with severe osteoarthritis of the hips. ( Costello, F; Eves, MJ; James, IG; Lloyd, RS; Miller, AJ, 1992) |
| "Paracetamol is ineffective in the treatment of low back pain and provides minimal short term benefit for people with osteoarthritis." | 2.52 | Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. ( Day, RO; Ferreira, ML; Ferreira, PH; Lin, CW; Machado, GC; Maher, CG; McLachlan, AJ; Pinheiro, MB, 2015) |
| " Low clinical heterogeneity was found for comparisons with low dosage of acetaminophen, normal dosage of NSAIDs, and moderate pain intensity at baseline." | 2.47 | NSAIDs vs acetaminophen in knee and hip osteoarthritis: a systematic review regarding heterogeneity influencing the outcomes. ( Bierma-Zeinstra, SM; Bohnen, AM; Koes, BW; Luijsterburg, PA; Verkleij, SP, 2011) |
| " A standardized form was used to abstract all data, including outcome measures of pain at rest, walking pain, and dropouts due to adverse effects." | 2.42 | A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. ( Balshaw, R; Barlas, S; Lee, C; Schnitzer, TJ; Straus, WL; Vogel, S, 2004) |
| "In 19 guidelines (10 for acute migraine, 9 for chronic knee OA) from 10 scientific societies (AAN/AHS, ACR/AF, CHS, EFNS, EHF/LTB, ESCEO, EULAR, SFEMC, SRF, OARSI) published between 1997 and 2021, methods, results and conclusions were compared, between guidelines and over time." | 1.72 | Practice guidelines for the treatment of acute migraine and chronic knee osteoarthritis with paracetamol: an expert appraisal on evolution over time between scientific societies. ( Attal, N; Desmeules, J; Eschalier, A; Lanteri-Minet, M; Perrot, S, 2022) |
| "The evaluation of the updated 'My Joint Pain' website didn't find significant improvements in terms of health education, but it may help delivering useful information about self-management and appropriate use of pharmacological treatments." | 1.56 | My joint pain, a web-based resource, effects on education and quality of care at 24 months. ( Bennell, KL; Dickson, C; Dobson, F; Fransen, M; Hunter, DJ; Jones, G; Urban, H; Wang, X, 2020) |
| "Tramadol is an option in the case patients will not respond satisfactorily to NSAIDs." | 1.39 | Pharmacologic treatment of hand-, knee- and hip-osteoarthritis. ( Bobacz, K, 2013) |
| "Important levels of fatigue are common in knee and hip OA patients." | 1.37 | Fatigue in knee and hip osteoarthritis: the role of pain and physical function. ( Arts-Sanders, MA; Defoort, KC; den Broeder, AA; Fransen, J; Snijders, GF; Stukstette, MJ; van den Ende, CH; van den Hoogen, FH; van Riel, PL, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.54) | 18.7374 |
| 1990's | 5 (7.69) | 18.2507 |
| 2000's | 21 (32.31) | 29.6817 |
| 2010's | 30 (46.15) | 24.3611 |
| 2020's | 8 (12.31) | 2.80 |
| Authors | Studies |
|---|---|
| da Costa, BR | 1 |
| Pereira, TV | 1 |
| Saadat, P | 1 |
| Rudnicki, M | 1 |
| Iskander, SM | 1 |
| Bodmer, NS | 1 |
| Bobos, P | 1 |
| Gao, L | 1 |
| Kiyomoto, HD | 1 |
| Montezuma, T | 1 |
| Almeida, MO | 1 |
| Cheng, PS | 1 |
| Hincapié, CA | 1 |
| Hari, R | 1 |
| Sutton, AJ | 1 |
| Tugwell, P | 1 |
| Hawker, GA | 1 |
| Jüni, P | 1 |
| Perrot, S | 1 |
| Eschalier, A | 1 |
| Desmeules, J | 1 |
| Lanteri-Minet, M | 1 |
| Attal, N | 1 |
| Weng, Q | 1 |
| Goh, SL | 1 |
| Wu, J | 1 |
| Persson, MSM | 1 |
| Wei, J | 1 |
| Sarmanova, A | 1 |
| Li, X | 1 |
| Hall, M | 1 |
| Doherty, M | 2 |
| Jiang, T | 1 |
| Zeng, C | 1 |
| Lei, G | 1 |
| Zhang, W | 2 |
| Endo, M | 1 |
| Kawahara, S | 1 |
| Sato, T | 1 |
| Tokunaga, M | 1 |
| Hara, T | 1 |
| Mawatari, T | 1 |
| Kawano, T | 1 |
| Zenda, S | 1 |
| Miyaji, T | 1 |
| Shimokawa, M | 1 |
| Sakamoto, S | 1 |
| Takano, T | 1 |
| Miyake, M | 1 |
| Aono, H | 1 |
| Nakashima, Y | 1 |
| Wang, X | 3 |
| Urban, H | 1 |
| Bennell, KL | 1 |
| Dickson, C | 1 |
| Dobson, F | 1 |
| Fransen, M | 1 |
| Jones, G | 1 |
| Hunter, DJ | 2 |
| Negrini, F | 1 |
| Negrini, S | 1 |
| Thorlund, JB | 1 |
| Roos, EM | 1 |
| Goro, P | 1 |
| Ljungcrantz, EG | 1 |
| Grønne, DT | 1 |
| Skou, ST | 1 |
| Mercier, E | 1 |
| Knoop, J | 1 |
| van Tunen, J | 1 |
| van der Esch, M | 1 |
| Roorda, LD | 1 |
| Dekker, J | 1 |
| van der Leeden, M | 1 |
| Lems, WF | 1 |
| Reed, K | 1 |
| Collaku, A | 1 |
| Moreira, S | 1 |
| Rasmussen, S | 1 |
| Diener, HC | 1 |
| Krebs, EE | 1 |
| Gravely, A | 1 |
| Nugent, S | 1 |
| Jensen, AC | 1 |
| DeRonne, B | 1 |
| Goldsmith, ES | 1 |
| Kroenke, K | 1 |
| Bair, MJ | 1 |
| Noorbaloochi, S | 1 |
| Brander, V | 1 |
| Skrepnik, N | 1 |
| Petrella, RJ | 1 |
| Jiang, GL | 1 |
| Accomando, B | 1 |
| Vardanyan, A | 1 |
| Leopoldino, AO | 1 |
| Machado, GC | 3 |
| Ferreira, PH | 2 |
| Pinheiro, MB | 2 |
| Day, R | 1 |
| McLachlan, AJ | 2 |
| Ferreira, ML | 3 |
| Onakpoya, IJ | 1 |
| Bobacz, K | 1 |
| Gimenez, S | 1 |
| Armada, B | 2 |
| Iturralde Iriso, J | 1 |
| Ginel Mendoza, L | 1 |
| Fernández-Morales, B | 1 |
| Prior, MJ | 1 |
| Harrison, DD | 1 |
| Frustaci, ME | 1 |
| Maher, CG | 2 |
| Lin, CW | 1 |
| Day, RO | 1 |
| Zheng, Y | 1 |
| Kostenbader, K | 1 |
| Barrett, T | 1 |
| Hisaw, E | 1 |
| Giuliani, MJ | 1 |
| Chen, Y | 1 |
| Young, JL | 1 |
| Adam, R | 1 |
| Veal, FC | 1 |
| Thompson, AJ | 1 |
| Steurer, J | 1 |
| Chou, R | 1 |
| Felson, D | 1 |
| Hofstede, SN | 2 |
| Vliet Vlieland, TP | 2 |
| van den Ende, CH | 3 |
| Nelissen, RG | 2 |
| Marang-van de Mheen, PJ | 2 |
| van Bodegom-Vos, L | 2 |
| Basedow, M | 1 |
| Williams, H | 1 |
| Shanahan, EM | 1 |
| Runciman, WB | 1 |
| Esterman, A | 1 |
| Altman, R | 1 |
| Hochberg, M | 1 |
| Gibofsky, A | 2 |
| Jaros, M | 1 |
| Young, C | 1 |
| Karlsson, M | 1 |
| Berggren, AC | 1 |
| Conaghan, PG | 1 |
| O'Brien, CM | 1 |
| Wilson, M | 1 |
| Schofield, JP | 1 |
| Verkleij, SP | 2 |
| Luijsterburg, PA | 1 |
| Bohnen, AM | 1 |
| Koes, BW | 1 |
| Bierma-Zeinstra, SM | 1 |
| Snijders, GF | 1 |
| Fransen, J | 1 |
| van Riel, PL | 1 |
| Stukstette, MJ | 1 |
| Defoort, KC | 1 |
| Arts-Sanders, MA | 1 |
| van den Hoogen, FH | 1 |
| den Broeder, AA | 1 |
| Endenburg, S | 1 |
| Konings, S | 1 |
| Oteo-Álvaro, A | 1 |
| Marín, MT | 1 |
| Ruiz-Ibán, MA | 1 |
| Rejas, J | 1 |
| Wegman, AC | 1 |
| van der Windt, DA | 1 |
| de Haan, M | 1 |
| Devillé, WL | 1 |
| Fo, CT | 1 |
| de Vries, TP | 1 |
| Wegman, A | 1 |
| van der Windt, D | 1 |
| van Tulder, M | 1 |
| Stalman, W | 1 |
| de Vries, T | 1 |
| Pincus, T | 3 |
| Koch, G | 1 |
| Lei, H | 1 |
| Mangal, B | 1 |
| Sokka, T | 3 |
| Moskowitz, R | 1 |
| Wolfe, F | 2 |
| Simon, L | 1 |
| Zlotnick, S | 1 |
| Fort, JG | 1 |
| Boureau, F | 1 |
| Schneid, H | 1 |
| Zeghari, N | 1 |
| Wall, R | 1 |
| Bourgeois, P | 1 |
| Arden, N | 1 |
| Bannwarth, B | 1 |
| Bijlsma, J | 1 |
| Gunther, KP | 1 |
| Hauselmann, HJ | 1 |
| Herrero-Beaumont, G | 1 |
| Jordan, K | 1 |
| Kaklamanis, P | 1 |
| Leeb, B | 1 |
| Lequesne, M | 1 |
| Lohmander, S | 1 |
| Mazieres, B | 2 |
| Martin-Mola, E | 1 |
| Pavelka, K | 1 |
| Pendleton, A | 1 |
| Punzi, L | 1 |
| Swoboda, B | 1 |
| Varatojo, R | 1 |
| Verbruggen, G | 1 |
| Zimmermann-Gorska, I | 1 |
| Dougados, M | 2 |
| Lee, C | 1 |
| Straus, WL | 1 |
| Balshaw, R | 1 |
| Barlas, S | 1 |
| Vogel, S | 1 |
| Schnitzer, TJ | 2 |
| Chung, C | 1 |
| Koch, GG | 2 |
| Bjordal, JM | 1 |
| Ljunggren, AE | 1 |
| Klovning, A | 1 |
| Slørdal, L | 1 |
| Malonne, H | 1 |
| Coffiner, M | 1 |
| Fontaine, D | 1 |
| Sonet, B | 1 |
| Sereno, A | 1 |
| Peretz, A | 1 |
| Vanderbist, F | 1 |
| Marshall, DA | 1 |
| Strauss, ME | 1 |
| Pericak, D | 1 |
| Buitendyk, M | 1 |
| Codding, C | 1 |
| Torrance, GW | 1 |
| Temple, AR | 1 |
| Benson, GD | 1 |
| Zinsenheim, JR | 1 |
| Schweinle, JE | 1 |
| Basskin, L | 1 |
| Seideman, P | 1 |
| Samuelson, P | 1 |
| Neander, G | 1 |
| Peloso, PM | 1 |
| Bellamy, N | 1 |
| Bensen, W | 1 |
| Thomson, GT | 1 |
| Harsanyi, Z | 1 |
| Babul, N | 1 |
| Darke, AC | 1 |
| Lefkowith, J | 1 |
| Jordan, JM | 1 |
| Luta, G | 1 |
| Callahan, LF | 1 |
| Schwartz, T | 1 |
| Abramson, SB | 1 |
| Caldwell, JR | 1 |
| Harrell, RA | 1 |
| Kremer, JM | 1 |
| Lautzenheiser, RL | 1 |
| Markenson, JA | 1 |
| Weaver, A | 1 |
| Cummins, P | 1 |
| Wilson, A | 1 |
| Morant, S | 1 |
| Fort, J | 1 |
| Hochberg, MC | 2 |
| Lynch, JM | 1 |
| Fox, TM | 1 |
| Dart, RC | 1 |
| Kuffner, EK | 1 |
| Blandino, D | 1 |
| Laroche, M | 1 |
| Moineuse, C | 1 |
| Durroux, R | 1 |
| Puget, J | 1 |
| Lloyd, RS | 1 |
| Costello, F | 1 |
| Eves, MJ | 1 |
| James, IG | 1 |
| Miller, AJ | 1 |
| Boissier, C | 1 |
| Perpoint, B | 1 |
| Laporte-Simitsidis, S | 1 |
| Mismetti, P | 1 |
| Hocquart, J | 1 |
| Gayet, JL | 1 |
| Rambaud, C | 1 |
| Queneau, P | 1 |
| Decousus, H | 1 |
| Vignon, E | 2 |
| Mathieu, P | 2 |
| Louisot, P | 1 |
| Richard, M | 2 |
| Charlet, C | 1 |
| Balblanc, JC | 1 |
| Amor, B | 1 |
| Benarrosh, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Patient-centered Treatment of Anxiety After Low-Risk Chest Pain in the Emergency Room[NCT04811521] | 375 participants (Anticipated) | Interventional | 2021-04-01 | Enrolling by invitation | |||
| Strategies for Prescribing Analgesics Comparative Effectiveness (SPACE) Trial[NCT01583985] | 265 participants (Actual) | Interventional | 2013-06-01 | Completed | |||
| Video-based, Patient-Focused Opioid Education in the Perioperative Period: A Feasibility Study[NCT03986866] | 110 participants (Actual) | Interventional | 2019-04-29 | Completed | |||
| Achieving Peri-Operative Pain Control Without Opioids[NCT04813991] | Phase 3 | 0 participants (Actual) | Interventional | 2022-03-15 | Withdrawn (stopped due to Enrollment was never initiated and the PI is leaving the institution so the study is closing.) | ||
| A Randomized, Double-Blind, Placebo-Controlled Study Evaluating Acetaminophen Extended Release (3900 mg/Day) in the Treatment of Osteoarthritis of the Hip or Knee.[NCT00240799] | Phase 3 | 542 participants (Actual) | Interventional | Completed | |||
| An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain[NCT01722864] | Phase 3 | 153 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| Immediate Effects of Manual Therapy Versus TENS in Patients With Knee Osteoarthritis[NCT02947451] | 54 participants (Actual) | Interventional | 2016-11-30 | Completed | |||
| A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Fixed-Dose, Parallel-Group, Efficacy, and Safety Study of Meloxicam SoluMatrix™ Capsules in Patients With Pain Due to Osteoarthritis of the Knee or Hip[NCT01787188] | Phase 3 | 403 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| An Open, Randomised, Multicentre Study to Compare Buprenorphine Transdermal Delivery System (BTDS) With Standard Treatment in Elderly Subjects With OA of the Hip and/or Knee[NCT00324038] | Phase 4 | 219 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| A Double Blind Cross-over Study of the Efficacy of a Proprietary Cherry Juice Blend in Osteoarthritis of the Knee.[NCT00443092] | Phase 4 | 59 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Astaxanthin Effects on Osteoarthritis Associated Pain and Inflammatory Indicators[NCT03664466] | 0 participants (Actual) | Interventional | 2021-04-29 | Withdrawn (stopped due to Inadequate funding) | |||
| Project Arthritis Recovering Quality of Life Through Education - Hip[NCT04018690] | 48 participants (Anticipated) | Interventional | 2019-09-01 | Not yet recruiting | |||
| The Minimal Effective Dose of Cis-9-cetylmyristoleate (CMO) in Persons Presenting With Knee Joint Pain[NCT02800759] | 28 participants (Actual) | Interventional | 2013-09-30 | Completed | |||
| Study of the Effect of Chondroitin Sulphate on Synovial Inflammation in Patients With Osteoarthritis of the Knee[NCT00604539] | Phase 3 | 70 participants (Anticipated) | Interventional | 2008-02-29 | Completed | ||
| Analgesic Effect of Ibuprofen 400 mg/Paracetamol 1000 mg, Ibuprofen 400 mg/ Paracetamol 1000 mg/60 mg Codeine, and Paracetamol 1000 mg/Codeine 60 mg: A Single-dose, Randomized, Placebo-controlled and Double-blind Study[NCT00921700] | Phase 4 | 200 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measure of pain-related functional interference (range 0-10; higher score is worse) (NCT01583985)
Timeframe: 3 months, 6 months, 9 months, and 12 months
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| 3 months | 6 months | 9 months | 12 months | |
| Non-opioid | 3.7 | 3.6 | 3.3 | 3.3 |
| Opioid | 3.7 | 3.4 | 3.6 | 3.4 |
Measure of pain intensity (range 0-10; higher score is worse) (NCT01583985)
Timeframe: 3 months, 6 months, 9 months, and 12 months
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| 3 months | 6 months | 9 months | 12 months | |
| Non-opioid | 4.0 | 4.1 | 3.6 | 3.5 |
| Opioid | 4.3 | 4.1 | 4.2 | 4.0 |
Checklist of bothersome medication-related symptoms (0-19, higher number = more symptoms) (NCT01583985)
Timeframe: 3 months, 6 months, 9 months, and 12 months
| Intervention | symptoms (Mean) | |||
|---|---|---|---|---|
| 3 months | 6 months | 9 months | 12 months | |
| Non-opioid | 1.3 | 1.3 | 0.9 | 0.9 |
| Opioid | 2.3 | 2.1 | 1.9 | 1.8 |
Feasibility of collecting data on the percentage of patients who develop chronic opioid use. This is measured as the number of patients who received an opioid prescription per the Arkansas prescription drug monitoring database during the 90-150 day period post operatively. (NCT03986866)
Timeframe: 90-150 days
| Intervention | Participants (Count of Participants) |
|---|---|
| No Video | 12 |
| Video | 5 |
Knowledge of Post operative Opioids after surgery via 7 day post operative phone call. Knowledge is measured on a scale of 1 to 10 with 10 being complete knowledge and 1 being no knowledge. (NCT03986866)
Timeframe: 7 days
| Intervention | units on a scale (Mean) |
|---|---|
| No Video | 8.32 |
| Video | 9.36 |
Post-operative pain control as determined by opioid utilization at three months. This is the number of patients that have discontinued opioids at the 3 month mark. (NCT03986866)
Timeframe: Up to 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| No Video | 47 |
| Video | 38 |
Feasibility of collecting data on the number of days until opioid cessation (NCT03986866)
Timeframe: Up to 3 months
| Intervention | days (Mean) |
|---|---|
| No Video | 13.9 |
| Video | 13.9 |
"The function in osteoarthritis subjects within the past 24 hours was measured at baseline using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) function subscale score. The WOMAC function subscale score is calculated as the mean of the visual analogue scale scores from 17 function subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their functional limitation level over the last 24 hours, with 0 mm meaning No Functional Limitation and 100 mm meaning Extreme Functional Limitation.~The WOMAC function subscale score difference was calculated as the WOMAC function subscale score assessed at Weeks 2, 6, and 12 minus the WOMAC function subscale score assessed at baseline." (NCT01787188)
Timeframe: Baseline to Week 12/Early Termination
| Intervention | mm (Least Squares Mean) |
|---|---|
| Meloxicam 5 mg Once Daily | -23.78 |
| Meloxicam 10 mg Once Daily | -21.70 |
| Placebo | -13.26 |
"The pain in subjects with osteoarthritis was measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score. The WOMAC pain subscale score is calculated as the average of the visual analogue scale (VAS) scores from 5 pain subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their pain level over the last 24 hours, with 0 mm representing No Pain and 100 mm representing Extreme Pain.~The WOMAC pain subscale score difference was calculated as the WOMAC pain subscale score assessed at Weeks 2, 6, and 12 minus the WOMAC pain subscale score assessed at baseline." (NCT01787188)
Timeframe: Baseline to Week 12/Early Termination
| Intervention | mm (Least Squares Mean) |
|---|---|
| Meloxicam 5 mg Once Daily | -30.51 |
| Meloxicam 10 mg Once Daily | -27.89 |
| Placebo | -20.07 |
"Pain, stiffness, and function in subjects with osteoarthritis were measured using the Western Ontario and McMaster Universities (WOMAC) Index, which is a 24-item questionnaire. The total (composite) WOMAC score is calculated as the average of the mean visual analogue scale (VAS) scores from the questions in the pain, stiffness, and function subscales. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their response to each of the questions, with 0 mm representing No Pain, Stiffness, or Difficulty and 100 mm representing Extreme Pain, Stiffness, and Difficulty.~The total WOMAC score difference was calculated as the total WOMAC score assessed at Weeks 2, 6, and 12 minus the total WOMAC score assessed at baseline." (NCT01787188)
Timeframe: Baseline to Week 12/Early Termination
| Intervention | mm (Least Squares Mean) |
|---|---|
| Meloxicam 5 mg Once Daily | -25.15 |
| Meloxicam 10 mg Once Daily | -22.83 |
| Placebo | -14.67 |
"The stiffness in osteoarthritis subjects within the past 24 hours was measured at baseline using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) stiffness subscale score. The WOMAC stiffness subscale score is calculated as the mean of the visual analogue scale scores from 2 stiffness subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their stiffness level over the last 24 hours, with 0 mm meaning No Stiffness and 100 mm meaning Extreme Stiffness.~The WOMAC stiffness subscale score difference was calculated as the WOMAC stiffness subscale score assessed at Weeks 2, 6, and 12 minus the WOMAC stiffness subscale score assessed at baseline." (NCT01787188)
Timeframe: Baseline to Week 12/Early Termination
| Intervention | mm (Least Squares Mean) |
|---|---|
| Meloxicam 5 mg Once Daily | -24.76 |
| Meloxicam 10 mg Once Daily | -21.33 |
| Placebo | -13.09 |
"The function in osteoarthritis subjects within the past 24 hours was measured at baseline using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) function subscale score. The WOMAC function subscale score is calculated as the mean of the visual analogue scale scores from 17 function subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their functional limitation level over the last 24 hours, with 0 mm meaning No Functional Limitation and 100 mm meaning Extreme Functional Limitation.~The WOMAC function subscale score difference was calculated as the WOMAC function subscale score assessed at Week 12/early termination minus the WOMAC function subscale score assessed at baseline." (NCT01787188)
Timeframe: Baseline to Week 12/Early Termination
| Intervention | mm (Least Squares Mean) |
|---|---|
| Meloxicam 5 mg Once Daily | -28.21 |
| Meloxicam 10 mg Once Daily | -28.40 |
| Placebo | -17.95 |
"The pain in subjects with osteoarthritis was measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score. The WOMAC pain subscale score is calculated as the average of the visual analogue scale (VAS) scores from 5 pain subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their pain level over the last 24 hours, with 0 mm representing No Pain and 100 mm representing Extreme Pain.~The WOMAC pain subscale score difference is calculated as the WOMAC pain subscale score assessed at Week 12 minus the WOMAC pain subscale score assessed at baseline." (NCT01787188)
Timeframe: Baseline to Week 12/Early Termination
| Intervention | mm (Least Squares Mean) |
|---|---|
| Meloxicam 5 mg Once Daily | -36.52 |
| Meloxicam 10 mg Once Daily | -34.41 |
| Placebo | -25.68 |
"Pain, stiffness, and function in subjects with osteoarthritis were measured using the Western Ontario and McMaster Universities (WOMAC) Index, which is a 24-item questionnaire. The total WOMAC score is calculated as the average of the mean visual analogue scale (VAS) scores from the questions in the pain, stiffness, and function subscales. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their response to each of the questions, with 0 mm representing No Pain, Stiffness, or Difficulty and 100 mm representing Extreme Pain, Stiffness, and Difficulty.~The total WOMAC score difference was calculated as the total WOMAC score assessed at Week 12/early termination minus the total WOMAC score assessed at baseline." (NCT01787188)
Timeframe: Baseline to Week 12/Early Termination
| Intervention | mm (Least Squares Mean) |
|---|---|
| Meloxicam 5 mg Once Daily | -29.85 |
| Meloxicam 10 mg Once Daily | -29.71 |
| Placebo | -19.72 |
"The stiffness in osteoarthritis subjects within the past 24 hours was measured at baseline using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) stiffness subscale score. The WOMAC stiffness subscale score is calculated as the mean of the visual analogue scale scores from 2 stiffness subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their stiffness level over the last 24 hours, with 0 mm meaning No Stiffness and 100 mm meaning Extreme Stiffness.~The WOMAC stiffness subscale score difference was calculated as the WOMAC stiffness subscale score assessed at Week 12/early termination minus the WOMAC stiffness subscale score assessed at baseline." (NCT01787188)
Timeframe: Baseline to Week 12/Early Termination
| Intervention | mm (Least Squares Mean) |
|---|---|
| Meloxicam 5 mg Once Daily | -29.68 |
| Meloxicam 10 mg Once Daily | -28.10 |
| Placebo | -18.74 |
"The function in osteoarthritis subjects within the past 24 hours was measured at baseline using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) function subscale score. The WOMAC function subscale score is calculated as the mean of the visual analogue scale scores from 17 function subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their functional limitation level over the last 24 hours, with 0 mm meaning No Functional Limitation and 100 mm meaning Extreme Functional Limitation.~The WOMAC function subscale score difference was calculated as the WOMAC function subscale score assessed at Week 2 minus the WOMAC function subscale score assessed at baseline." (NCT01787188)
Timeframe: Baseline to Week 2
| Intervention | mm (Least Squares Mean) |
|---|---|
| Meloxicam 5 mg Once Daily | -20.45 |
| Meloxicam 10 mg Once Daily | -14.41 |
| Placebo | -10.00 |
"The pain in subjects with osteoarthritis was measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score. The WOMAC pain subscale score is calculated as the average of the visual analogue scale (VAS) scores from 5 pain subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their pain level over the last 24 hours, with 0 mm representing No Pain and 100 mm representing Extreme Pain.~The WOMAC pain subscale score difference was calculated as the WOMAC pain subscale score assessed at Week 2 minus the WOMAC pain subscale score assessed at baseline." (NCT01787188)
Timeframe: Baseline to Week 2
| Intervention | mm (Least Squares Mean) |
|---|---|
| Meloxicam 5 mg Once Daily | -26.12 |
| Meloxicam 10 mg Once Daily | -20.42 |
| Placebo | -16.51 |
"Pain, stiffness, and function in subjects with osteoarthritis were measured using the Western Ontario and McMaster Universities (WOMAC) Index, which is a 24-item questionnaire. The total WOMAC score is calculated as the average of the mean visual analogue scale (VAS) scores from the questions in the pain, stiffness, and function subscales. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their response to each of the questions, with 0 mm representing No Pain, Stiffness, or Difficulty and 100 mm representing Extreme Pain, Stiffness, and Difficulty.~The total WOMAC score difference was calculated as the total WOMAC score assessed at Week 2 minus the total WOMAC score assessed at baseline." (NCT01787188)
Timeframe: Baseline to Week 2
| Intervention | mm (Least Squares Mean) |
|---|---|
| Meloxicam 5 mg Once Daily | -21.62 |
| Meloxicam 10 mg Once Daily | -15.67 |
| Placebo | -11.28 |
"The stiffness in osteoarthritis subjects within the past 24 hours was measured at baseline using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) stiffness subscale score. The WOMAC stiffness subscale score is calculated as the mean of the visual analogue scale scores from 2 stiffness subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their stiffness level over the last 24 hours, with 0 mm meaning No Stiffness and 100 mm meaning Extreme Stiffness.~The WOMAC stiffness subscale score difference was calculated as the WOMAC stiffness subscale score assessed at Week 2 minus the WOMAC stiffness subscale score assessed at baseline." (NCT01787188)
Timeframe: Baseline to Week 2
| Intervention | mm (Least Squares Mean) |
|---|---|
| Meloxicam 5 mg Once Daily | -19.84 |
| Meloxicam 10 mg Once Daily | -14.88 |
| Placebo | -8.86 |
"The function in osteoarthritis subjects within the past 24 hours was measured at baseline using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) function subscale score. The WOMAC function subscale score is calculated as the mean of the visual analogue scale scores from 17 function subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their functional limitation level over the last 24 hours, with 0 mm meaning No Functional Limitation and 100 mm meaning Extreme Functional Limitation.~The WOMAC function subscale score difference was calculated as the WOMAC function subscale score assessed at Week 6 minus the WOMAC function subscale score assessed at baseline." (NCT01787188)
Timeframe: Baseline to Week 6
| Intervention | mm (Least Squares Mean) |
|---|---|
| Meloxicam 5 mg Once Daily | -24.41 |
| Meloxicam 10 mg Once Daily | -24.38 |
| Placebo | -14.73 |
"The pain in subjects with osteoarthritis was measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score. The WOMAC pain subscale score is calculated as the average of the visual analogue scale (VAS) scores from 5 pain subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their pain level over the last 24 hours, with 0 mm representing No Pain and 100 mm representing Extreme Pain.~The WOMAC pain subscale score difference was calculated as the WOMAC pain subscale score assessed at Week 6 minus the WOMAC pain subscale score assessed at baseline." (NCT01787188)
Timeframe: Baseline to Week 6
| Intervention | mm (Least Squares Mean) |
|---|---|
| Meloxicam 5 mg Once Daily | -31.31 |
| Meloxicam 10 mg Once Daily | -30.82 |
| Placebo | -20.98 |
"Pain, stiffness, and function in subjects with osteoarthritis were measured using the Western Ontario and McMaster Universities (WOMAC) Index, which is a 24-item questionnaire. The total WOMAC score is calculated as the average of the mean visual analogue scale (VAS) scores from the questions in the pain, stiffness, and function subscales. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their response to each of the questions, with 0 mm representing No Pain, Stiffness, or Difficulty and 100 mm representing Extreme Pain, Stiffness, and Difficulty.~The total WOMAC score difference was calculated as the total WOMAC score assessed at Week 6 minus the total WOMAC score assessed at baseline." (NCT01787188)
Timeframe: Baseline to Week 6
| Intervention | mm (Least Squares Mean) |
|---|---|
| Meloxicam 5 mg Once Daily | -25.86 |
| Meloxicam 10 mg Once Daily | -25.45 |
| Placebo | -16.03 |
"The stiffness in osteoarthritis subjects within the past 24 hours was measured at baseline using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) stiffness subscale score. The WOMAC stiffness subscale score is calculated as the mean of the visual analogue scale scores from 2 stiffness subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their stiffness level over the last 24 hours, with 0 mm meaning No Stiffness and 100 mm meaning Extreme Stiffness.~The WOMAC stiffness subscale score difference was calculated as the WOMAC stiffness subscale score assessed at Week 6 minus the WOMAC stiffness subscale score assessed at baseline." (NCT01787188)
Timeframe: Baseline to Week 6
| Intervention | mm (Least Squares Mean) |
|---|---|
| Meloxicam 5 mg Once Daily | -26.52 |
| Meloxicam 10 mg Once Daily | -23.39 |
| Placebo | -14.30 |
The primary efficacy variable was the average daily pain score recorded on a Box Scale-11 pain scale in the evening. 0 = no pain and 10 = most pain imaginable. Subjects ticked the box from 0 - 10 which best describes their level of pain. (NCT00324038)
Timeframe: every day over a 12 week study duration.
| Intervention | Box Scale 11 boxes (Mean) |
|---|---|
| Buprenorphine Transdermal System | 3 |
| Co-codamol Tablets | 3 |
13 reviews available for acetaminophen and Coxarthrosis
| Article | Year |
|---|---|
Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis.
Topics: Acetaminophen; Administration, Oral; Administration, Topical; Aged; Analgesics, Opioid; Anti-Inflamm | 2021 |
Comparative efficacy of exercise therapy and oral non-steroidal anti-inflammatory drugs and paracetamol for knee or hip osteoarthritis: a network meta-analysis of randomised controlled trials.
Topics: Acetaminophen; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Exercise Therapy; Humans; | 2023 |
NSAIDs are superior to paracetamol for osteoarthritic pain and function in a network meta-analysis.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Humans; Network Me | 2018 |
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Humans; Network Meta-Analysis; Osteoarthriti | 2018 |
Paracetamol versus placebo for knee and hip osteoarthritis.
Topics: Acetaminophen; Aged; Analgesics, Non-Narcotic; Arthralgia; Humans; Liver; Middle Aged; Osteoarthriti | 2019 |
Paracetamol as first line for treatment of knee and hip osteoarthritis.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Humans; Knee Joint; Osteoarthritis, Hip; Osteoarthritis, Kn | 2020 |
Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Humans; Low Back Pain; Neck Pain; Osteoarthritis, Hip; Oste | 2015 |
NSAIDs vs acetaminophen in knee and hip osteoarthritis: a systematic review regarding heterogeneity influencing the outcomes.
Topics: Acetaminophen; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Humans; Midd | 2011 |
Nonsteroidal antiinflammatory drugs or acetaminophen for osteoarthritis of the hip or knee? A systematic review of evidence and guidelines.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Evidence-Based Medicine; Humans; Osteoarthri | 2004 |
EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Ste | 2005 |
EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Ste | 2005 |
EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Ste | 2005 |
EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Ste | 2005 |
EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Ste | 2005 |
EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Ste | 2005 |
EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Ste | 2005 |
EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Ste | 2005 |
EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Ste | 2005 |
A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inh | 2004 |
Pharmacological therapy of osteoarthritis.
Topics: Acetaminophen; Anthraquinones; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Chondr | 2001 |
What a difference a year makes: reflections on the ACR recommendations for the medical management of osteoarthritis.
Topics: Acetaminophen; Acupuncture; Anti-Inflammatory Agents, Non-Steroidal; Complementary Therapies; Cycloo | 2001 |
24 trials available for acetaminophen and Coxarthrosis
28 other studies available for acetaminophen and Coxarthrosis
| Article | Year |
|---|---|
Practice guidelines for the treatment of acute migraine and chronic knee osteoarthritis with paracetamol: an expert appraisal on evolution over time between scientific societies.
Topics: Acetaminophen; Chronic Pain; Humans; Migraine Disorders; Osteoarthritis, Hip; Osteoarthritis, Knee; | 2022 |
My joint pain, a web-based resource, effects on education and quality of care at 24 months.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Australia; Female; Follow- | 2020 |
Is paracetamol better than placebo for knee and hip osteoarthritis? A Cochrane review summary with commentary.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Humans; Knee Joint; Osteoarthritis, Hip | 2020 |
Patients use fewer analgesics following supervised exercise therapy and patient education: an observational study of 16 499 patients with knee or hip osteoarthritis.
Topics: Acetaminophen; Aged; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Confid | 2021 |
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Humans; Osteoarthr | 2016 |
Analgesic use in patients with knee and/or hip osteoarthritis referred to an outpatient center: a cross-sectional study within the Amsterdam Osteoarthritis Cohort.
Topics: Acetaminophen; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Cross-Sectional Studies; F | 2017 |
Pharmacologic treatment of hand-, knee- and hip-osteoarthritis.
Topics: Acetaminophen; Administration, Oral; Administration, Topical; Adrenal Cortex Hormones; Analgesics; A | 2013 |
Clinical management of patients with hip and knee osteoarthritis: patient satisfaction with treatment switch.
Topics: Acetaminophen; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studi | 2014 |
Danger of generalising findings on paracetamol for low back pain.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Humans; Low Back Pain; Neck Pain; Osteoarthritis, Hip; Oste | 2015 |
Paracetamol should remain the first line option for persistent pain.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Humans; Low Back Pain; Neck Pain; Osteoarthritis, Hip; Oste | 2015 |
Authors' reply to Adam and to Veal and Thompson.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Humans; Low Back Pain; Neck Pain; Osteoarthritis, Hip; Oste | 2015 |
[Paracetamol is ineffective for back pain and only minimally effective for osteoarthritis].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Humans; Low Back Pain; Neck Pain; Osteoarthritis, Hip; Oste | 2015 |
ACP Journal Club. Review: Acetaminophen reduces pain in hip or knee osteoarthritis by a small amount, but not low back pain.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Humans; Low Back Pain; Neck Pain; Osteoarthritis, Hip; Oste | 2015 |
Paracetamol is ineffective for spinal pain and knee and hip osteoarthritis.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Humans; Low Back Pain; Neck Pain; Osteoarthritis, Hip; Oste | 2015 |
Variation in use of non-surgical treatments among osteoarthritis patients in orthopaedic practice in the Netherlands.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cross-Sectional Studies; Diet Therapy; | 2015 |
Australian GP management of osteoarthritis following the release of the RACGP guideline for the non-surgical management of hip and knee osteoarthritis.
Topics: Acetaminophen; Adult; Aged; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Australia; | 2015 |
Barriers and Facilitators Associated with Non-Surgical Treatment Use for Osteoarthritis Patients in Orthopaedic Practice.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Cross-Sectional Studies; Female; Guideline Adherence; Human | 2016 |
[Paracetamol in knee and hip arthrosis is dispensable].
Topics: Acetaminophen; Diclofenac; Etoricoxib; Humans; Naproxen; Osteoarthritis, Hip; Osteoarthritis, Knee; | 2016 |
Fatigue in knee and hip osteoarthritis: the role of pain and physical function.
Topics: Acetaminophen; Activities of Daily Living; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-S | 2011 |
Comments on the article by Conaghan et al.
Topics: Acetaminophen; Analgesics; Buprenorphine; Codeine; Female; Humans; Male; Osteoarthritis, Hip; Osteoa | 2012 |
[Update on current care guidelines: knee and hip osteoarthriti].
Topics: Acetaminophen; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida | 2012 |
NSAIDs, including coxibs, probably do more harm than good, and paracetamol is ineffective for hip OA.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Humans; Osteoarth | 2005 |
Comparison of a scheduled narcotic for chronic pain with a similar medication for breakthrough pain only is not a clinically relevant comparison.
Topics: Acetaminophen; Chronic Disease; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Therapy, Co | 2006 |
Use of acetaminophen in the treatment of osteoarthritis in patients with liver disease: comment on the 2000 update of the American College of Rheumatology recommendations for management of hip and knee osteoarthritis.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Humans; Liver Diseases; Osteoarthritis, Hip; Osteoarthritis | 2001 |
Use of acetaminophen in alcoholic patients: comment on the 2000 update of the American College of Rheumatology recommendations for management of hip and knee osteoarthritis.
Topics: Acetaminophen; Alcoholism; Analgesics, Non-Narcotic; Humans; Osteoarthritis, Hip; Osteoarthritis, Kn | 2001 |
Are NSAIDs more effective than acetaminophen in patients with osteoarthritis?
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2001 |
Can ischemic hip disease cause rapidly destructive hip osteoarthritis? A case report.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement, Hip; Codein | 2002 |
In vitro effect of nonsteroidal antiinflammatory drugs on proteoglycanase and collagenase activity in human osteoarthritic cartilage.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Diclofenac; Endo | 1991 |